Introduction
Congenital anophthalmia and microphthalmia result from failure of early eye development.
One-third of affected individuals are syndromic [1] , [2] and it is genetically heterogeneous. [3] Xlinked syndromic anophthalmia and microphthalmia have been shown to result from pathogenic variants in four genes: BCOR [4] (MIM:300485, MCOPS2), HCCS [5] (MIM:300056, MCOPS7), HMGB3 [6] (MIM:300193, MCOPS13), and NAA10 [7] (MIM:309800, MCOPS1). A fifth locus, MCOPS4 (MIM:301590, also designated as ANOP1), with linkage to Xq27-q28, was specified without identification of an associated gene. HMGB3 and NAA10 reside on Xq27-Xq28. A single HGMB3 variant has been reported in one family to cause syndromic colobomatous microphthalmia. [6] Forrester et al. described a family segregating what they termed Lenz microphthalmia syndrome (LMS) and linkage to Xq27-q28. [8] Affected individuals had severe microphthalmia, renal anomalies, high-arched palate, cutaneous syndactyly of the hands, and severe intellectual disability (ID). A c.471+2T>A splice variant in NAA10 was identified as causative, the only study to date associating NAA10 variants with syndromic microphthalmia. [7] The MCOPS4 locus was originally defined based on a family reported by Graham et al. [9] Their manifestations included microphthalmia/anophthalmia and ID in multiple affected males.
Here, we re-analyze this family using genetic linkage analysis and exome sequencing, verified our findings in two additional families, and functionally characterized the variants.
Materials and Methods
This study was approved by Institutional Review Boards at the National Institutes of Health, the UK Multicentre Research Ethics Committee (MREC), the University of Michigan, the University of California, Davis, and the Huntingdon Ethics Committee, UK. All DNA analyses were performed using standard techniques.
Linkage and haplotype analyses
Resampling and repeat genetic linkage analyses were performed in family 1 ( Figure 1A ) using 30 microsatellite markers on the X chromosome. Initial analyses of 22 markers spanning the X chromosome were followed by fine mapping with an additional eight markers from the region near Xqtel. LOD scores were computed using FASTLINK using equal marker allele frequencies. [10] , [11] , [12] For multi-marker analyses, inter-marker recombination fractions were derived from the Rutgers map. [13] The disease locus was modeled as X-linked recessive.
Analyses were performed under two additional possible scenarios, first that the individual I-2 was gonadal mosaic and second that penetrance was less than 100%. Haplotype analysis was performed assuming a model of X-linked recessive inheritance.
Sequence analyses
The coding region and consensus splice sites of two candidate genes, NAA10 and HMGB3, were analyzed in family 1 using Sanger sequencing. Exome sequencing was performed on individual IV-3 and his parents at the NIH Intramural Sequencing Center (NISC), as described. [14] Identified variants in the linkage region were filtered for quality, absence in ExAC males and absence in 473 males from an in-house dataset. [15] , [16] Sanger sequence analyses were performed in family 1 to confirm segregation. Targeted Sanger sequencing of NAA10 was performed in the proband of family 2 ( Figure 1B ). Independently, sequence analysis of a panel of 41 genes causally associated with severe eye malformations was carried out on the proband in family 3 ( Figure 1C ) using a custom-designed Agilent SureSelect panel (Agilent Technologies, Inc., Santa Clara, CA) and paired-end DNA sequencing using an Illumina MiSeq platform (Illumina, San Diego, CA), as per the manufacturer's instructions. Targeted sequencing of the NAA10 polyadenylation signal (PAS) was performed in 250 unrelated microphthalmia/anophthalmia/coloboma patients selected without sex bias from the MRC Human Genetics Unit Eye Malformation cohort. A further 126 males with developmental eye disorders underwent targeted sequencing of the NAA10 PAS. Forty-four of these individuals with bilateral developmental eye disorders were analysed for variants in the coding region and consensus splice sites of NAA10.
X-inactivation analyses
X-inactivation studies were performed on genomic DNA from 11 carrier females (family 1   individuals I-2, II-2, II-6, II-17, III-15; family 2 individuals III-2, III-3, IV-1, IV-5, V-8; family 3 individual I-2) using the human androgen receptor (HUMARA) assay as described in Allen et al [17] with minor modifications. Briefly, genomic DNA was digested with Rsa1 either alone or with the addition of HpaII (New England Biolabs, Ipswich, MA). Digested DNA was PCR amplified using primers HUMAR_F: /56-FAM/TCCAGAATCTGTTCCAGAGCGTGC and Humara_R:
GCTGTGAAGGTTGCTGTTCCTCAT (Integrated DNA Technologies, Inc. Coralville, Iowa). Products were run on an 3130xl genetic analyzer (ThermoFisher Scientific, Waltham, MA) and analyzed using GeneMapper v4.0 (ThermoFisher Scientific, Waltham, MA).
RNA Analyses
Total RNA was isolated from whole blood from affected and carrier individuals in family 1 and from unrelated male and female controls using PAXgene Blood RNA tubes (BD Biosciences, San Jose, CA). Total RNA was isolated from lymphoblasts from one affected and one unaffected individual in family 2 using the RNeasy Mini kit (Qiagen, Germantown, MD). RNA samples were not available from family 3. RNA-Seq libraries were constructed from 0.5-1 µg total RNA after rRNA depletion using Ribo-Zero Globin (Illumina, San Diego, CA). The Illumina TruSeq Stranded Total RNA Kit was used according to manufacturer's instructions. The cDNA inserts were ~200 bp after chemical shearing. PCR amplification was performed using 10 cycles. Unique barcode adapters were applied to each library. Libraries were pooled in equimolar ratio for sequencing.
The pooled libraries were sequenced on multiple lanes of a HiSeq 2500 (Illumina, San Diego, CA) using version 4 chemistry to achieve a minimum of 69 million 125 base read pairs. The data were processed using RTA version 1.18.64 and CASAVA 1.8.2. RNA-Seq reads were aligned with the STAR aligner, [18] using the hg19 genome assembly and the Ensembl transcript database (release 74). The STAR BAM output file was converted to WIG format using the bam2wig.py script from the RSeqC suite, [19] and these WIG files were further converted to bigwig format using the wigToBigWig tool from the UCSC Genome Browser's binary utilities directory.
For quantitative PCR (qPCR), 400 ng total RNA was converted to cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems, Beverly, MA). TaqMan assays were performed using 10 ng cDNA, gene specific TaqMan probes (NAA10: HS01125831_g1 and HA00185854_m1; beta-Actin: Hs99999903_m1 (Thermo Fisher Scientific, Waltham, MA)) and TaqMan Gene Expression Master Mix (Applied Biosytems, Beverly, MA) on the OneStepPlus Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA). Samples were run in triplicate and relative expression levels in affected and carrier individuals as compared to control individuals were calculated using the delta-delta Ct method.
Results

Clinical evaluations
Family 1
Family 1 ( Figure 1A ) was originally described by Graham et al. in support of a fifth microphthalmia/anophthalmia locus MCOPS4. The family was reported to include seven affected males with microphthalmia/anophthalmia and ID. [9] One male, II-18, was reported to have normal eyes with cleft soft palate and a single ear tag and was considered unaffected with respect to syndromic anophthalmia/microphthalmia. An additional affected male, IV-3, with a milder phenotype as compared to his affected uncles, was born after publication of the Graham et al paper. [9] Briefly, this male infant was born following a pregnancy in which scans were assessed to be normal. However, at birth he was noted to have a large open neural tube defect (NTD), right sided anophthalmia, and bilateral 2-3 cutaneous syndactyly of his toes. When his teeth erupted they were irregular. He was sociable and did not show signs of the severe developmental delay or behavioral problems, most notably self-mutilation, seen in other affected males in the family.
Family 2
Family 2 ( Figure 1B ) was originally described by Slavotinek et al. [20] as a four-generation family with X-linked anophthalmia consistent with linkage to Xq27. The intelligence of two living males in family 2 was apparently normal. Carrier females III-2 and IV-1 had unremarkable eye examinations, individual IV-1 was diagnosed with dyslexia but her intelligence was apparently normal.
Family 3
The male proband (individual II-2, Figure 1C ) was the second child of a non-consanguineous couple, referred for diagnostic screening of genes associated with severe eye malformations.
Family history was remarkable for a maternal uncle with anencephaly. The proband presented with spina bifida at 20 weeks gestation. He was a term delivery with birth weight 3.2 Kg. At birth, he was noted to have widely spaced eyes, unilateral phthisis bulbi, downturned corners of the mouth, small penis, and small feet with upturned nails. At eight months his length, weight, and head circumference were recorded at 9 th centile. He had a repaired myelomeningocele, hydrocephalus with a ventriculoperitoneal shunt, and left grade 2 vesicoureteric reflux with a normal renal ultrasound. MRI studies showed ventriculomegaly with a Chiari type 2 malformation. Developmental milestones were reported to be normal at 8 months. Array CGH was reported as normal.
Molecular Data
Family 1
LOD score analyses reported in the original paper showed a peak logarithm of odds (LOD) score of 1.9, between the disease and markers on Xq27-q28, below the 2.0 threshold recommended to declare X-chromosome linkage. [21] The evidence of linkage was weak unless one assumed non-penetrance, pleiotropy, variable expressivity, or gonadal mosaicism as the mutant haplotype was shared by II-18 and his affected relatives.
Repeat multi-marker analysis using four informative markers DXS8091, DXS1193, DXS8086, and DXS1073 achieved a peak LOD score of 1.43 with the disease locus placed on top of DXS1073 and assuming full penetrance. The peak multi-marker score was 2.19 with 75% penetrance, unaffected. Querying the gnomAD database for variants in the consensus PAS for NAA10 did not identify any variants in over 170,000 alleles.
Family 2
A reexamination of the linkage data showed that family 1 and family 2 had overlapping regions near Xqtel consistent with linkage. Based on the findings in family 1, targeted Sanger sequencing of NAA10 was performed in the proband of family 2. A second distinct variant in the the 3'UTR of NAA10, chrX:g.153,195,401T>C, c.*39A>G, was identified, which altered the consensus PAS from AATAAA to GATAAA. The variant was verified by Sanger sequencing in carrier females and was not present in two unaffected males.
Family 3
Targeted sequencing of 41 genes causally associated with severe eye malformations in the proband from family 3 identified a third variant in NAA10, chrX:g.153,195,400T>C , c.*40A>G, that altered the consensus PAS from AATAAA to AGTAAA. The NAA10 variant in family 3 was confirmed by Sanger sequencing. DNA from the uncle with anencephaly was not available for testing.
NAA10 Sequence Analysis in Microphthalmia/Anophthalmia/Coloboma Cohorts
Targeted sequencing of the NAA10 PAS in 250 unrelated microphthalmia/anophthalmia/coloboma patients selected without sex bias from the MRC Human Genetics Unit Eye Malformation cohort did not identify additional variants. No variants affecting the NAA10 PAS were identified in a further 126 males with developmental eye disorders. In addition, no pathogenic variants in the coding region and consensus splice sites of NAA10 were identified in 44 of these individuals who presented with bilateral developmental eye disorders.
X-Inactivation
Four of 11 carrier females showed greater than 90% skewing of X-inactivation, individual II-2 from family 1 and individuals III-2, IV-1 and IV-5 from family 2. However, females did not show consistent skewing of X-inactivation.
RNA analyses
The consequences of the PAS variants for NAA10 mRNA expression level and structure were investigated using qPCR and RNAseq in families 1 and 2. qPCR showed carrier females from family 1 to have similar levels of NAA10 RNA as compared to control individuals. In contrast, 
Discussion
Six protein complexes, NatA through NatF, carry out N α acetylation of proteins in the cell. [23] , [24] NAA10 is the primary subunit of the NatA complex and an auxiliary subunit of the NatE complex. [24] , [25] The acetylation targets of the six complexes are believed to be mostly distinct and dependent on the amino acids that follow the methionine in position 1. [24] Additionally, data from a knock-out mouse model suggests that NAA10 plays a role in the regulation of methylation through direct DNA binding. [26] Prior to the present publication, the mutational spectrum in NAA10 comprised nine missense alterations and the single splice site variant identified previously in a single family with what those authors called LMS. The first reported variant in NAA10, c.109T>C; p.(Ser37Pro), was identified in two families segregating a sex-linked recessive male lethal syndrome with an aged appearance and cardiac arrhythmias. [27] Eight additional missense variants have since been reported in heterozygous females or hemizygous males with developmental delay and/or ID with or without cardiac involvement and without anophthalmia. [28] , [29] , [30] , [31] , [32] The majority of these variants were identified as de novo alterations. [28] , [30] , [31] , [32] Functional studies of the missense alterations have demonstrated a variable effect on the ability of NAA10 to acetylate substrates and the clinical phenotype may correlate with the level of acetylation dysfunction and affected substrates. Alternatively, clinically relevant predicted missense variants in NAA10 have been shown to disrupt DNA binding [26] and it is likely that different missense alterations will variably contribute to this phenomenon.
The polyA_DB database contains human mRNA polyadenylation sites based on EST/cDNA evidence [33] and predicts four sites in the 3' region of NAA10. Based on the NAA10 Poly(A) sequence data in the UCSC Genome Browser, the PAS at c.*39 -c.*44 is the most commonly used signal with polyadenylation occurring between 12-19 nucleotides 3' of that hexamer.
Three distinct nucleotides within this six-nucleotide signal are mutated in the families described here. Previous in vitro studies have demonstrated that these changes in the PAS hexamer disrupt both cleavage and polyadenylation (Figure 4 ). [34] Furthermore, these variants are analogous to variants associated with abnormal phenotypes in other genes. The Table 1 ). [35] The 3'UTR variant of NAA10 identified in family 2, c.*39A>G, alters the AATAAA consensus to GATAAA, similar to another reported pathogenic variant in the HBB gene, (c.*108A>G, HGMD CR127145). [36] The NAA10 3'UTR variant identified in family 3 , c.*40A>G, alters the AATAAA consensus to AGTAAA, similar to the variant in the ARSA gene (HGMD CR890137) reported by Gieselmann et al [37] and a variant in the SLC6A4 gene (HGMD CR102248) reported by Gyawali et al [38] although it is important to note that the wild-type PAS consensus sequence in both ARSA and SLC6A4 genes is AATAAC, (See Table 1 ). That the NAA10 variant disrupts a consensus PAS rather than a non-canonical PAS could be consistent with the observation that the NAA10 variants are associated with a Mendelian disorder whereas the ARSA and SLC6A4 variants are associated with lower penetrance traits.
All three families presented here manifested microphthalmia/anophthalmia with variable additional features. In family 1, individuals had variable expressivity ranging from syndromic microphthalmia/anophthalmia with severe ID to isolated cleft palate and an ear tag. suggested this variable expressivity may result from the role of NAA10 in global methylation. [26] The role of NAA10 in global methylation may contribute to the observed variable expressivity in these families as well. Specifically, the observed phenotype may result from the regions of the genome experiencing defective methylation in any one individual. As methylation is important in the etiology of NTDs it is interesting to speculate that the role of NAA10 in global methylation may account for the NTDs seen in these families. Future studies will be needed to determine if methylation or other factors play a role in the variable expressivity seen with these variants.
Cleavage and polyadenylation signals reside in the 3' UTRs of mRNAs and include a number of key cis elements including the AAUAAA PAS which typically resides 10-30 nucleotides upstream of the cleavage site (reviewed in [39] , [40] ). Ninety percent of identified PAS conform to the hexanucleotide sequence AAUAAA and most of the remaining 10% differ by only a single substitution. [39] The AAUAAA hexamer is critical both for cleavage and poly(A) addition, [41] and the effects of point mutations in this hexamer have been determined. [34] Disease-associated variants in PAS are rare and consequently we were surprised to identify three such variants in this rare disorder. To identify all known consensus PAS variants, we performed a directed search of the Human Gene Mutation Database (HGMD). [42] We identified 31 reported PAS variants in 19 genes (Table 1) , 23 associated with Mendelian disorders and eight associated with a functional polymorphism or susceptibility. Overall, PAS variants account for 23 out of the ~195,000 DM variants in HGMD, or 0.012% of the total. As well as being individually uncommon, such variants have a highly non-random distribution across genes. Of the 23 variants associated with Mendelian disorders, nine are in HBB, four are in HBA2, and two are in FOXP3, the remainder being singletons. Some of this distribution can be explained by the depth and detail to which the various genes have been studied, HBB being one of the best studied of all human genes. To allow for this, the proportion of polyadenylation variants to all known pathogenic variants in a given gene can be tabulated. When expressed in this way, a very different pattern emerges. NAA10 has the highest proportion of PAS variants, at 25%. The next highest cluster of genes includes IGF1, NAT1, BMP1, and SLC6A4, each of which has a single PAS variant, but a relatively small overall number of variants, yielding a high proportion. HBB and HBA2 lie in the middle of the range at about 1% of variants, reflecting the large number of variants in these well-studied genes. Most of the clinical phenotypes associated with PAS variants are typical of those seen for loss of function variants in the same gene although they may be found with milder forms of the phenotypes -for example, in HBB, [36] , [ 43] the phenotypes of PAS variants are described as either typical or mild thalassemia. The contribution to milder phenotypes has two implications, first in disorders where loss of gene function would be lethal, PAS variants may allow sufficient function for viability. Second, for disorders where the phenotype is due to complete loss of function, PAS variants may be missed if they lead to a milder condition. [36] We conclude from these data that the phenotypic consequence of pathogenic PAS variants is likely due to loss or partial loss of function, consistent with the experimental observations of these variants in other genes and the qPCR data we show here. Specifically, for NAA10, this suggests that partial loss of protein function due to reduced mRNA levels leads to a distinct phenotype, as compared to missense variants where the functional deficiency may only affect specific acetylation or DNA binding functions. The previously reported NAA10 splice site variant [7] also showed reduced mRNA/protein supporting reduced function as causal for the microphthalmia phenotype.
Alternatively, sequences within the elongated 3' end, or within the retained intron 7 for the splice variant, may have a novel functional effect. Possible novel effects include: altered RNA or protein localization [44] , altered 3'UTR-directed protein-protein interactions [45] , or acquisition of novel regulatory functions. However, since the retained sequences are distinct between the splice site variant and the PAS variants, a novel property of the mRNA is unlikely to be the mechanism accounting for the overlapping feature of microphthalmia. Additionally, the absence of a phenotype in carrier females without skewed X-inactivation suggests that any effect would need to fit a recessive model of inheritance. The general dearth of recognized PAS pathogenic variants may be in part due to the inherent difficulty in identifying PAS. In addition, many such variants may not be included in next generation sequence data due to the limitations of exome sequencing kits and the predominant use of exome over genome sequencing.
The assessment of pathogenicity for non-coding variants in Mendelian disorders is challenging. The ACMG/AMP [46] framework includes few criteria that are relevant to 3' UTR variants, reflecting a focus on high penetrance coding variants. For the variants we identified here, we invoked criteria PS3 (well-established in vitro or in vivo functional studies), PM1 (located in a mutational hot spot and/or critical and well-established functional domain), PM2
(absent from controls), and PP1 (co-segregation with disease in multiple affected family members). As qPCR is not "a well-established functional assay" because qPCR for NAA10 is not established in the diagnostic realm, the PS3 criteria can be downgraded to a moderate level of evidence (PS3_Mod). Additionally, our segregation data are arguably less than robust considering that we have invoked variable expressivity to explain the occurrence of the variant in II-18 in family 1 and thus PP1 might arguably be dropped. That would leave PS3_Mod, PM1, and PM2, which combine to yield a likely pathogenic assessment. Based on these pieces of evidence, we conclude that these three PAS variants are likely pathogenic.
These data have important implications for the overall process of identifying pathogenic variation. We hypothesize that PAS variants are candidate pathogenic variants for many Mendelian disorders and may be a component of the mutational spectrum of patients who are currently 'mutation-negative'. A full assessment of this hypothesis will first require the continued development of genome (as opposed to exome) population sequence reference databases, allowing a greater understanding of the evolutionary constraints operating at 3' UTR loci. Second, robust methods to identify PAS for all genes will need to be developed. While trivial for many genes, this is challenging for others as some use multiple polyadenylation sites and often the PAS sequence does not conform to the consensus, as demonstrated for a number of the genes that we reviewed. Third, to the extent that exome analysis continues to outpace genome analysis, it will be necessary to target these sequences in exome capture reagents.
Fourth, testing laboratories will need to direct their attention to detecting and interpreting such variants. Finally, criteria for pathogenicity of non-coding variants will need to be updated. We believe that the accomplishment of these improvements in variant detection, interrogation, and interpretation will allow the findings based on the three variants reported here as a cause of a rare disorder to yield benefits for the diagnosis of patients with many other genetic disorders and contribute to the overall improvement in clinical genomic sequencing diagnostic yield.
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